61985-25-9 Usage
Description
1-(1H-Imidazol-4-yl)-ethanone HCl, also known as Imidazolone, is an organic compound derived from the essential oil of Mirabilis Jalapa root. It is a photochemical compound with a unique chemical structure that consists of an imidazole ring attached to an ethanone group. 1-(1H-Imidazol-4-yl)-ethanone HCl exhibits various properties that make it suitable for a range of applications across different industries.
Uses
Used in Pharmaceutical Industry:
1-(1H-Imidazol-4-yl)-ethanone HCl is used as an active pharmaceutical ingredient for its potential therapeutic effects. 1-(1H-Imidazol-4-yl)-ethanone HCl's unique structure allows it to interact with specific biological targets, making it a promising candidate for the development of new drugs to treat various diseases and medical conditions.
Used in Chemical Synthesis:
1-(1H-Imidazol-4-yl)-ethanone HCl serves as a key intermediate in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its versatile chemical structure enables it to be used as a building block for the creation of a wide range of molecules with diverse applications.
Used in Research and Development:
As a photochemical compound, 1-(1H-Imidazol-4-yl)-ethanone HCl is utilized in research laboratories for studying its properties, reactivity, and potential applications. Researchers can use this compound to explore new reaction pathways, develop innovative synthetic methods, and gain insights into the underlying mechanisms of various chemical processes.
Used in Analytical Chemistry:
1-(1H-Imidazol-4-yl)-ethanone HCl can be employed as a reference compound or a standard in analytical chemistry for the calibration of instruments and the development of new analytical methods. Its unique chemical structure and properties make it a valuable tool for the accurate determination of various parameters in chemical analysis.
Used in Material Science:
1-(1H-Imidazol-4-yl)-ethanone HCl's photochemical properties and unique structure make it a potential candidate for the development of new materials with specific properties. It can be used in the design and synthesis of advanced materials for applications in areas such as electronics, optics, and sensors.
Check Digit Verification of cas no
The CAS Registry Mumber 61985-25-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,9,8 and 5 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 61985-25:
(7*6)+(6*1)+(5*9)+(4*8)+(3*5)+(2*2)+(1*5)=149
149 % 10 = 9
So 61985-25-9 is a valid CAS Registry Number.
InChI:InChI=1/C5H6N2O.ClH/c1-4(8)5-2-6-3-7-5;/h2-3H,1H3,(H,6,7);1H
61985-25-9Relevant articles and documents
Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer
Belluti, Federica,Bisi, Alessandra,Caciolla, Jessica,Fimognari, Carmela,Gobbi, Silvia,Magistrato, Alessandra,Martini, Silvia,Pavlin, Matic,Rampa, Angela,Simonelli, Federica,Spinello, Angelo,Turrini, Eleonora,Zaffaroni, Nadia
supporting information, (2021/08/09)
Breast Cancer (BC) is a leading cause of death in women, currently affecting 13% of female population worldwide. First-line clinical treatments against Estrogen Receptor positive (ER+) BC rely on suppressing estrogen production, by inhibiting the aromatase (AR) enzyme, or on blocking estrogen-dependent pro-oncogenic signaling, by targeting Estrogen Receptor (ER) α with selective Modulators/Degraders (SERMs/SERDs). The development of dual acting molecules targeting AR and ERα represents a tantalizing alternative strategy to fight ER + BC, reducing the incidence of adverse effects and resistance onset that limit the effectiveness of these gold-standard therapies. Here, in silico design, synthesis, biological evaluation and an atomic-level characterization of the binding and inhibition mechanism of twelve structurally related drug-candidates enable the discovery of multiple compounds active on both AR and ERα in the sub-μM range. The best drug-candidate 3a displayed a balanced low-nanomolar IC50 towards the two targets, SERM activity and moderate selectivity towards a BC cell line. Moreover, most of the studied compounds reduced ERα levels, suggesting a potential SERD activity. This study dissects the key structural traits needed to obtain optimal dual acting drug-candidates, showing that multitarget compounds may be a viable therapeutic option to counteract ER + BC.
SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS
-
Page/Page column 48, (2010/11/30)
The present invention relates to compounds of general formula (I) wherein A, B, L, R1, R2, R3a and R3b are defined as in the specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.
A GENERAL SYNTHESIS OF 4(5)-ACYLIMIDAZOLES FROM 4-ACYLAMINOISOXAZOLES.
Reiter, Lawrence A.
, p. 3423 - 3426 (2007/10/02)
2-Substituted-4(5)-acyl, 1,2-disubstituted 4-acyl and 1,2-disubstituted-5-acylimidazoles can be specifically prepared from 4-aminoisoxazoles.
